

A New Approach to the Furan Degradation Problem Involving Ozonolysis of the *trans*-Enedione and Its Use in a Cost-Effective Synthesis of Eplerenone


Bruce A. Pearlman,^{*,†} Amphlett G. Padilla, John T. Hach, Jeffrey L. Havens, and Muniraj D. Pillai

Chemical Research and Development, Pfizer, Incorporated,
Kalamazoo, Michigan 49001-0102

bruce.pearlman@spcorp.com

Received February 28, 2006 (Revised Manuscript Received March 23, 2006)

ABSTRACT



Whereas ozonization of furan 3a affords little or no carboxylic acid 5, ozonization of the corresponding *trans*-enedione 6 afforded carboxylic acid 5 in 82.4% yield (cryst., overall from furan, 100 g scale; after workup with dimethyl sulfide, followed by mildly basic hydrogen peroxide). This new approach to furan degradation is showcased in a cost-effective synthesis of eplerenone, an important new medicine for cardiovascular indications.

Since the discovery over 50 years ago that hypertension and congestive heart failure are caused by excessive levels of circulating aldosterone,^{1,2} pharmaceutical research organizations have sought to discover selective aldosterone blockers.³ In 1985, the search culminated with the discovery of eplerenone (**1**) by scientists at CIBA-Geigy.⁴ However,

because the dosage is relatively high, it was necessary to develop a particularly efficient manufacturing process to make this medicine accessible to the worldwide patient population at an acceptable cost. Herein is reported a cost-effective synthesis of eplerenone, the active pharmaceutical ingredient of INSPRA, a new medicine for the treatment of hypertension and congestive heart failure.⁵

In designing a synthesis of eplerenone, the principal challenge is the introduction of the carbomethoxy substituent. In the first published synthesis,⁴ this was accomplished by Nagata hydrocyanation of $\Delta^{9(11)}$ -canrenone (**2a**), but the stereoselectivity was at best $\sim 4:1$ $7\alpha/\beta$, necessitating chromatography.⁶ In the other published synthesis,⁷ the car-

[†] Current address: Schering-Plough Research Institute, 1011 Morris Ave., Union, NJ 07083.

(1) (a) Luetscher, J. A., Jr.; Deming, Q. B. *J. Clin. Invest.* **1950**, *29*, 1576. (b) Luetscher, J. A., Jr.; Neher, R.; Wettstein, A. *Experientia* **1954**, *10*, 456. (c) Reviews: Gaunt, R.; Renzi, A. A.; Chart, J. J. *J. Clin. Endocrinol. Metab.* **1955**, *15*, 621. Cross, R. *J. Am. J. Med.* **1956**, *21*, 423.

(2) Reviews on the pharmacology of aldosterone: (a) Rudolph, A. E.; Rocha, R.; McMahon, E. G. *Mol. Cell. Endocrinol.* **2004**, *217*, 229. (b) McMahon, E. G. *Curr. Pharm. Des.* **2003**, *9*, 1065. (c) Rocha, R.; Funder, J. W. *Ann. N. Y. Acad. Sci.* **2002**, *970*, 89. (d) McMahon, E. G. *Curr. Opin. Pharm.* **2001**, *1*, 190. (e) Delyani, J. A. *Kidney Int.* **2000**, *57*, 1408.

(3) Historical review of the discovery of eplerenone: Garthwaite, S. M.; McMahon, E. G. *Mol. Cell. Endocrinol.* **2004**, *217*, 27.

(4) (a) Grob, J.; Boillaz, M.; Schmidlin, J.; Wehrli, H.; Wieland, P.; Fuhrer, H.; Rihs, G.; Joss, U.; de Gasparo, M.; Haenni, H.; Ramjoue, H. P.; Whitebread, S. E.; Kalvoda, J. *Helv. Chim. Acta* **1997**, *80*, 566. (b) Grob, J.; Kalvoda, J. U.S. Patent 4,559,332, December 17, 1985.


(5) Patent application covering this research: Pearlman, B. A.; Padilla, A. G.; Havens, J. L.; Mackey, S. S.; Wu, H. US 2003/0232981 A1, December 18, 2003.

(6) Reference 4a reports that $\Delta^{9(11)}$ -canrenone undergoes hydrocyanation with Et₂AlCN stereoselectively from the α face. We have made numerous attempts to reproduce this claim and consistently observed $7\alpha/\beta$ ratios of no more than $\sim 4/1$. See Supporting Information.

bomethoxy group was introduced stereoselectively via 4,6-bishydrocyanation of 11 α -hydroxycanrenone (**2c**), but regioselective dehydration of the 11 α hydroxyl was problematic. Thus, a need existed for a new method for the introduction of a carbon substituent at C-7 of the steroid nucleus.

Furylation was investigated as an alternative to hydrocyanation because the furan ring has frequently been employed as a surrogate for carboxylic acid in natural product total synthesis.⁸ To effect conjugate furylation in high yield, it was necessary to employ the protic Lewis acid conditions of Poirier and Dujardin,⁹ as no reaction occurred under aprotic Lewis acid conditions (e.g., TiCl₄, CH₂Cl₂, -30 °C). Four dienone substrates were studied (**2a–d**; Table 1). The

Table 1. Furylation of Steroidal Dienones



dienone	X	Y	7 α / β ^a	yield ^b (%)
$\Delta^9(11)$ -canrenone	2a	π bond	91/9	72.9
$\Delta^9(11)$ -canrenone	2a	π bond	92/8	77.7 ^c
canrenone	2b	H H	78/22	69.5 ^d
11 α -hydroxycanrenone	2c	H OH	99/1	86.2 ^e
9(11 α)-epoxycanrenone	2d	-O-	89/11	75.5

^a Determined by LC analysis of the crude product mixture at the reaction endpoint. ^b Yield of α isomer after isolation/purification. ^c Solvent was acetonitrile. ^d Reaction time was 88 h, with double the amount of reagents. ^e Average of two runs.

most cost-effective results were obtained with $\Delta^9(11)$ -canrenone **2a** because it is readily synthesized from crude soy sterols by a short sequence of microbiological¹⁰ and chemical¹¹ steps and, although furylation was not completely stereoselective ($\alpha/\beta = 91/9$), the β adduct is efficiently removed because it is an oil. A single crystallization of the crude product afforded crystals of **3a** that contained no more than 0.1% of the β isomer or any other impurity, with the loss of only 4.1% yield of the α isomer to the filtrate. Although 11 α -hydroxycanrenone **2c** undergoes furylation more stereoselectively ($\alpha/\beta = 99/1$),¹² the adduct **3c** is difficult to dehydrate to **3a** regioselectively.

(7) Ng, J. S.; Wang, P. T.; Baez, J. A.; Liu, C.; Anderson, D. K.; Lawson, J. P.; Erb, B.; Wieczorek, J.; Mucciariello, G.; Vanzanella, F.; Kunda, S. A.; Letendre, L. J.; Pozzo, M. J.; Sing, Y.-L. L.; Yonan, E. E. U.S. Patent 6,180,780 B1, January 30, 2001.

(8) Lipshutz, B. H. *Chem. Rev.* **1986**, *86*, 795.

(9) (a) Poirier, J.-M.; Dujardin, G. *Heterocycles* **1987**, *25*, 399. (b) Dujardin, G.; Poirier, J.-M. *Bull. Soc. Chim. Fr.* **1994**, *131*, 900.


(10) Vovcha, M. G.; Antosz, F. J.; Knight, J. C.; Kominek, L. A.; Pyke, T. R. *Biochim. Biophys. Acta* **1978**, *531*, 308.

(11) (a) Beaton, J. M.; Huber, J. E.; Padilla, A. G.; Breuer, M. E. U.S. Patent 4,127,596, November 28, 1978. (b) Miller, P. C.; Pozzo, M. J.; Chou, S. K. US 2004/0024202 A1, February 5, 2004.

(12) The anomalously high 7 α selectivity is attributable to a destabilizing interaction between the incipient 7 β bond and the carbon–oxygen bond in the transition state leading to the 7 β isomer, see: Cieplak, A. S. *Chem. Rev.* **1999**, *99*, 1265.

Although furan is a popular surrogate for carboxylic acid in synthesis, no general method exists for unmasking. Two methods are most frequently used: (1) periodate/catalytic RuO₂,¹³ and (2) ozonization. However, the former method requires a large molar excess of periodate, which is prohibitively expensive for commercial applications, and the latter gives highly variable yields (11–89% depending on the other functionality in the substrate).¹⁴ Attempts to degrade furan adduct **3a** by ozonization (5/1 MeOH/CH₂Cl₂, -78 °C) resulted in rapid and selective cleavage of the distal double bond to give enol acetate **4** (as a 1:1 mixture of epimers) cleanly, followed by slower and apparently nonselective cleavage of the three remaining double bonds to give a complex mixture of polar products containing little or none of the desired carboxylic acid **5** (Scheme 1). Thus, a more

Scheme 1. Standard Ozonization Approach to Furan Degradation



effective method for the degradation of furans to carboxylic acids was needed.

Because furan **3a** can be opened to the enedione *cis*-**6**, which can be isomerized to *trans*-**6** in high yield (see Scheme 2 for conditions), degradation of both *cis*-**6** and *trans*-**6** was studied. It was found that ozone cleaves the enedione double bond of *trans*-**6** cleanly to give (after reduction of the hydroperoxide)¹⁵ the α -ketoaldehyde methanol adduct **7** in essentially pure form. Baeyer–Villiger oxidation with basic hydrogen peroxide¹⁶ gave the carboxylic acid **5** in 82.4% yield (crystallized, overall from **3a**, without isolation of any


(13) (a) Mukaiyama, T.; Tsuzuki, R.; Kato, J. *Chem. Lett.* **1985**, 837 [yield of carboxylic acid from furan: 78%]. (b) Dondoni, A.; Junquera, F.; Merchan, F. L.; Merino, P.; Scherrmann, M.-C.; Tejero, T. *J. Org. Chem.* **1997**, *62*, 5484 [51–69%]. (c) Dondoni, A.; Franco, S.; Junquera, F.; Merchan, F. L.; Merino, P.; Tejero, T. *J. Org. Chem.* **1997**, *62*, 5497 [46–87%].

(14) (a) Schmid, G.; Fukuyama, T.; Akasaka, K.; Kishi, Y. *J. Am. Chem. Soc.* **1979**, *101*, 259 [yield of carboxylic acid from furan: 55%]. (b) Asher, V.; Becu, C.; Anteunis, M. J. O.; Callens, R. *Tetrahedron Lett.* **1981**, *22*, 141 [30%]. (c) Danishefsky, S.; Maring, C. *J. Am. Chem. Soc.* **1985**, *107*, 7762 [50%]. (d) Dziewiszek, K.; Zamojski, A. *Carbohydr. Res.* **1986**, *150*, 163 [11%]. (e) Ramalingam, K.; Nanjappan, P.; Kalvin, D. M.; Woodard, R. W. *Tetrahedron* **1988**, *44*, 5597 [80%]. (f) Kusakabe, M.; Kitano, Y.; Kobayashi, Y.; Sato, F. *J. Org. Chem.* **1989**, *54*, 2085 [87–95%]. (g) Bodurow, C. C.; Boyer, B. D.; Brennan, J.; Bunnell, C. A.; Burks, J. E.; Carr, M. A.; Doecke, C. W.; Eckrich, T. M.; Fisher, J. W.; Gardner, J. P.; Graves, B. J.; Hines, P.; Hoying, R. C.; Jackson, B. G.; Kinnick, M. D.; Kochert, C. D.; Lewis, J. S.; Luke, W. D.; Moore, L. L.; Morin, J. M., Jr.; Nist, R. L.; Prather, D. E.; Sparks, D. L.; Vladuchick, W. C. *Tetrahedron Lett.* **1989**, *30*, 2321 [77%]. (h) Dondoni, A.; Marra, A.; Scherrmann, M.-C. *Tetrahedron Lett.* **1993**, *34*, 7323 [40–60%]. (i) Caron, S.; Stoermer, D.; Mapp, A. K.; Heathcock, C. H. *J. Org. Chem.* **1996**, *61*, 9126 [0%]. (j) Kruger, J.; Carreira, E. M. *Tetrahedron Lett.* **1998**, *39*, 7013 [78–87%].

(15) The ratio of hydroxyhydroperoxide **11** to alcohol **7** in the crude ozonolysate was 31.9/68.1.

(16) (a) Nukaya, H.; Inaoka, Y.; Ishida, H.; Tsuji, K.; Suwa, Y.; Wakabayashi, K.; Kosuge, T. *Chem. Pharm. Bull.* **1993**, *41*, 649. (b) Hollingsworth, R. I. *J. Org. Chem.* **1999**, *64*, 7633.

Scheme 2. Stepwise Approach to Furan Degradation



intermediates, without chromatography, 100 g scale). Careful pH control was necessary in the crystallization of the carboxylic acid to avoid isomerization to the bridged lactone **8**, as lactonization is catalyzed by both strong acid (e.g., 0.05 equiv PhSO₃H, CH₂Cl₂, Δ) and buffers (e.g., 0.1 equiv pyridine, CH₂Cl₂, Δ). However, bridged lactone **8** opens back to carboxylic acid **5** under the conditions of the next step (esterification). Thus, rather than isolate carboxylic acid **5**, it is preferable to allow it to convert to the bridged lactone **8** in the crystallization by intentionally adding a catalytic amount of benzenesulfonic acid. A run carried out in this manner afforded pure **8** in 81.3% yield (crystallized, overall from **3a**, without isolation of any intermediates, without chromatography, 100 g scale).¹⁷ To complete the synthesis, either carboxylic acid **5** or bridged lactone **8** is treated with aq bicarbonate to give the carboxylic acid potassium salt, which is treated with dimethyl sulfate to give the methyl ester **9**, which is epoxidized⁷ to give eplerenone **1**.


Compound *cis*-**6** underwent degradation to **5** in significantly lower yield than *trans*-**6** (86.1% vs 97.4%). This is attributed to competitive ozonolysis of the two nuclear double bonds on the basis of a set of competition experiments, which established that *cis*-**6** undergoes ozonolysis ~8 times more slowly than *trans*-**6** (-59 °C, 1:1 MeOH/CH₂Cl₂).

(17) Alternatively, methoxyhydroperoxide **4** can be degraded to lactone **8** in 44.8% yield (unoptimized) by the following sequence: (1) Me₂S (MeOH/CH₂Cl₂, rt, 1 h); (2) evaporation of excess Me₂S and CH₂Cl₂; (3) H₂O₂ in the amount of 7 equiv (5 equiv KHCO₃, aq MeOH, rt). This alternative furan degradation method has much potential and deserves further study.

(18) This side reaction was unexpected, as simple α-hydroperoxy-α-methoxyketones rearrange cleanly to carboxylic acids in mild base: (a) Bailey, P. S.; Bath, S. S. *J. Am. Chem. Soc.* **1957**, *79*, 3120. (b) Bailey, P. S.; Mainthia, S. B.; Abshire, C. J. *J. Am. Chem. Soc.* **1960**, *82*, 6136. (c) Bailey, P. S.; Chang, Y.-G. *J. Org. Chem.* **1962**, *27*, 1192. (d) Yamamoto, H.; Miura, M.; Nojima, M.; Kusabayashi, S. *J. Chem. Soc., Perkin Trans. I* **1986**, 173.

The unusual reductive/oxidative workup of the ozonolysate requires explanation. Workup with mildly basic H₂O₂ gave mixtures of **5** and α-ketoester **12**, formed by the dehydration of **11** (Scheme 3).¹⁸ However, treatment of **7** with mildly

Scheme 3. Reactivity of Methoxy- vs Hydroxy-Hydroperoxide



basic H₂O₂ gave **5** cleanly, presumably via **10**. Thus, the key to clean Baeyer–Villiger cleavage is to treat the crude ozonolysate with Me₂S to reduce **11** to **7** prior to treatment with mildly basic H₂O₂.¹⁹

Because *trans*-enediones are highly electrophilic and ozone is also electrophilic,²⁰ the preference of ozone for attacking the *trans*-enedione over the more electron-rich nuclear double bonds is noteworthy. Presumably the pendant enedione is attacked selectively because it is less sterically shielded than the other double bonds. Steric effects on olefin ozonization rates have been documented.^{20b,e}

In summary, an efficient process for the synthesis of eplerenone, a new medicine for the treatment of hypertension and congestive heart failure, is described. The process features a novel approach to furan degradation involving opening/isomerization to the *trans*-enedione, ozonization/reduction to the α-ketoaldehyde, and Baeyer–Villiger oxidation to the carboxylic acid. The success of this approach to furan degradation should encourage the broader use of furan as a synthon for carboxylic acid in organic synthesis.

Acknowledgment. We are grateful to our Pfizer colleagues Dr. Stephen H. Grode for spectroscopic support, Dr. John G. Hoogerheide for analytical support, and Dr. Thomas A. Runge for project direction.

Supporting Information Available: Experimental procedures; compound characterization data; ¹³C and ¹H NMR spectra for all new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

OL060503V

(19) Use of acetic acid as the carbonyl oxide trap instead of methanol allows the dimethyl sulfide reduction step to be omitted, but the yield of **5** was only 78%.

(20) (a) Wibaut, J. P.; Sixma, F. L. *J. Recueil* **1952**, *71*, 761. (b) Vrbaski, T.; Cvetanovic, R. J. *Can. J. Chem.* **1960**, *38*, 1053. (c) Williamson, D. G.; Cvetanovic, R. J. *J. Am. Chem. Soc.* **1968**, *90*, 3668, 4248. (d) Whitworth, A. J.; Ayoub, R.; Rousseau, Y.; Fliszar, S. *J. Am. Chem. Soc.* **1969**, *91*, 7128. (e) Pryor, W. A.; Giamalva, D.; Church, D. F. *J. Am. Chem. Soc.* **1985**, *107*, 2793.